Product
Makya, our solution for data-driven de novo drug design
Makya is a SaaS (software-as-a-service) platform designed for chemists to provide them with de-novo drug design tools.
- Biotech and Lifescience
Iktos is a global leader in artificial intelligence and robotics for drug discovery. Its generative AI technology designs molecules in silico, optimized to meet all key success criteria of a discovery project. Available as SaaS software and through strategic collaborations with pharmaceutical companies, Iktos combines AI-driven molecular design with robotic synthesis and biological testing, accelerating drug discovery. With over 60 successful projects to date, Iktos is also advancing its own pipeline of drug candidates in oncology, obesity and metabolism, inflammatory and autoimmune diseases. Iktos completed a €15.5M Series A financing round, co-led by M Ventures and Debiopharm Innovation, with participation from Omnes Capital.
Business Domain / 分野
Business Type / 業種
Disease Area / 疾患領域
Modalities / モダリティ
Technologies / 技術
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術
Product
Makya, our solution for data-driven de novo drug design
Makya is a SaaS (software-as-a-service) platform designed for chemists to provide them with de-novo drug design tools.
Product
Spaya, our solution for data-driven synthesis planning
Spaya is our cutting-edge AI-driven retrosynthesis platform that transforms target compounds into commercially available starting materials.